Akari Therapeutics (AKTX) Receivables - Other (2015 - 2017)

Akari Therapeutics (AKTX) has reported Receivables - Other for 3 consecutive years, with $2.7 million the latest figure, recorded in Q4 2017.

• Quarterly Receivables - Other changed N/A year-over-year to $2.7 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $2.7 million (changed N/A YoY) and the FY2017 annual result came in at $2.7 million, changed N/A from the prior year.
• Receivables - Other improved to $2.7 million in Q4 2017 per AKTX's latest filing, from $10502.0 in the prior quarter.
• Over the last five years, Receivables - Other for AKTX reached as high as $2.7 million in Q4 2017 and fell as low as $10366.0 in Q4 2015.
• A 3-year average of $502597.5 and a median of $76358.5 in 2015 frame the typical range for Receivables - Other.
• The largest YoY upside for Receivables - Other was 92.45% in 2016 against a maximum downside of 92.6% in 2016.
• Year by year, Receivables - Other stood at $10366.0 in 2015, then rose by 1.31% to $10502.0 in 2016, then soared by 25609.39% to $2.7 million in 2017.
• According to Business Quant data, Receivables - Other over the past three periods registered $2.7 million, $10502.0, and $10717.0 for Q4 2017, Q2 2016, and Q1 2016 respectively.